Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer

被引:13
|
作者
Planas, Jacques [1 ]
Celma, Ana [1 ]
Placer, Jose [1 ]
Cuadras, Merce [1 ]
Regis, Lucas [1 ]
Gasanz, Carlos [1 ]
Trilla, Enrique [1 ]
Salvador, Carlos [1 ]
Lorente, David [1 ]
Morote, Juan [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Vall dHebron, Dept Urol, Barcelona, Spain
关键词
Androgen deprivation therapy; castration level; luteinizing hormone; prostate cancer; testosterone; SERUM TESTOSTERONE; CESSATION; AGONIST; TIME; MEN; NORMALIZATION; SUPPRESSION; WITHDRAWAL; CARCINOMA; TRENDS;
D O I
10.1080/21681805.2016.1227876
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to evaluate hormonal recovery after cessation of androgen deprivation therapy (ADT) in a group of elderly prostate cancer patients. Materials and methods: Forty patients with locally advanced or metastatic prostate cancer, with a mean age of 71.5 years [95% confidence interval (CI) 69.1-73.9], were treated with ADT for a mean duration of 74.6 months (95% CI 59.7-89.5 months). Mean follow-up time after ADT cessation was 36.5 months (95% CI 30.6-42.3 months). Serum testosterone and luteinizing hormone (LH) were determined at 6 month intervals after ADT cessation. Results: After 18 months of follow-up, all patients had recovered normal LH levels, while 38% of patients still presented castration levels of testosterone (< 50 ng/dl). A multivariate analysis was performed to find factors related to testosterone recovery (testosterone >50 ng/dl). Neither age at start of ADT nor clinical stage reached statistical significance. Only time under ADT was correlated with testosterone recovery (p = .031). Kaplan-Meier curves were obtained. Mean time for testosterone recovery was 14.5 months (95% CI 6.5-22.6 months) in patients treated with ADT for less than 60 months compared to 29.3 months (95% CI 19.6-39.1 months) in patients treated with ADT for more than 60 months (log-rank p = .029). Conclusions: Age did not correlate with testosterone recovery in a group of elderly prostate cancer patients in whom ADT was stopped. Testosterone recovery after ADT cessation was significantly correlated with time under ADT treatment. Significant implications related to economic aspects of the dosage schedule may be considered.
引用
收藏
页码:425 / 428
页数:4
相关论文
共 50 条
  • [31] Quality of life and testosterone recovery after androgen deprivation therapy in patients with high-risk prostate cancer: Long-term data from a phase III trial
    Nabid, Abdenour
    Carrier, Nathalie
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Vavassis, Peter
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Souhami, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial
    Abdenour Nabid
    Nathalie Carrier
    André-Guy Martin
    Jean-Paul Bahary
    Peter Vavassis
    Sylvie Vass
    Boris Bahoric
    Robert Archambault
    François Vincent
    Redouane Bettahar
    Luis Souhami
    Quality of Life Research, 2025, 34 (3) : 725 - 737
  • [33] Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate Cancer
    Kohutek, Zachary A.
    Weg, Emily S.
    Pei, Xin
    Shi, Weiji
    Zhang, Zhigang
    Kollmeier, Marisa A.
    Zelefsky, Michael J.
    UROLOGY, 2016, 87 : 146 - 152
  • [34] Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer
    Nascimento, Bruno
    Miranda, Eduardo P.
    Jenkins, Lawrence C.
    Benfante, Nicole
    Schofield, Elizabeth A.
    Mulhall, John P.
    JOURNAL OF SEXUAL MEDICINE, 2019, 16 (06): : 872 - 879
  • [35] Biochemical Response to Androgen Deprivation Therapy Before External Beam Radiation Therapy Predicts Long-term Prostate Cancer Survival Outcomes
    Zelefsky, Michael J.
    Gomez, Daniel R.
    Polkinghorn, William R.
    Pei, Xin
    Kollmeier, Marisa
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (03): : 529 - 533
  • [36] OSTEOPOROSIS IN PATIENTS WITH PROSTATE CANCER ON LONG-TERM ANDROGEN DEPRIVATION THERAPY: AN INCREASING BUT UNDER-RECOGNISED PROBLEM Reply
    Brown, Janet E.
    Sherriff, Jennifer M.
    James, Nicholas D.
    BJU INTERNATIONAL, 2010, 106 (05) : 727 - 727
  • [37] The role of insulin in castrate resistant progression of advanced prostate cancer in patients receiving long-term androgen deprivation therapy
    Mckenzie, I.
    Nelson, C.
    Swindle, P.
    BJU INTERNATIONAL, 2012, 109 : 59 - 59
  • [38] Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer
    Gilbert, Stephen E.
    Tew, Garry A.
    Fairhurst, Caroline
    Bourke, Liam
    Saxton, John M.
    Winter, Edward M.
    Rosario, Derek J.
    BRITISH JOURNAL OF CANCER, 2016, 114 (04) : 401 - 408
  • [39] Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer
    Stephen E Gilbert
    Garry A Tew
    Caroline Fairhurst
    Liam Bourke
    John M Saxton
    Edward M Winter
    Derek J Rosario
    British Journal of Cancer, 2016, 114 : 401 - 408
  • [40] Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report
    Markowski, Mark C.
    Imus, Philip
    Wright, Jean L.
    Schottenstein, Douglas
    Paller, Channing J.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (05) : E839 - E842